News & Information For Arrhythmia Clinicians
|Falls in older people QS86- March 2015|
|Transient loss of consciousness
('blackouts') in over 16s- October 2014
|Falls in older people: assessing risk and prevention CG161- June 2013|
|AliveCor Heart Monitor and AliveECG app (Kardia Mobile) for detecting atrial fifibrillation|
NICE Guidelines- Anticoagulants
NICE quality standards
NICE quality standards are a concise set of prioritised statements designed to drive measurable quality improvements within a particular area of health or care. They are derived from high quality guidance such as that from NICE or other sources accredited by NICE.
Click here to learn more about NICE quality standards.
View guidance relating to cardiac arrhythmias
September 2014: Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system and the INRatio2 PT/INR monitor) (DG14)
June 2014: Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (review of TA95 and TA120)
NICE value the contribution that members of the public make to their guidance and quality standards. If you would like to consider becoming a representative, please view the current opportunities:
Please visit the NICE website to view further news updates. Click here.
The Government’s mandate to NHS England for 2017-18
The NHS has a unique place at the heart of our society and is – by some distance – the institution that makes us most proud to be British.
It is because of this that the 2017-18 mandate to NHS England goes further than ever before to ensure that we not only deliver the best care and support to today’s NHS patients, but also deliver the reform and renewal needed to sustain the NHS for the future.
New specialised commissioning consultation launched
NHS England has today launched a consultation on four related policies that describe how NHS England will make decisions on funding for treatments that are not currently routinely commissioned. The four policies are: in-year service developments, individual funding requests, funding experimental and unproven treatments, and continuing funding after clinical trials.
A separate consultation - https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/consultation-on-changes-to-technology-appraisals-and-highly-specialised-technologies has also been launched today by NICE and NHS England jointly on changes to the arrangements for evaluating and funding drugs and other health technologies appraised through NICE’s Technology Appraisal (TA) and Highly Specialised Technologies (HST) programmes.